Astellas Oncology is committed to elevating the standard of cancer care. We focus on developing innovative, targeted therapies for hard-to-treat cancers with limited treatment options, which is where we see the greatest opportunity to help people living with cancer.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Please visit astrazeneca-us.com for more information.

Blueprint Medicines, a Sanofi Company, is a global precision therapy company that aims to invent transformative medicines for people with cancer and blood disorders. Applying an approach that is both precise and agile, we seek to create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate our scientific innovation into a broad pipeline of important approved and investigational precision therapies aimed at addressing difficult-to-treat cancers and blood disorders. Today, we are delivering our approved medicines to patients in the United States, Europe and in other geographies ourselves or through our partners.

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. 

About Caris Life Sciences

Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.

Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. 

Cencora, formerly AmerisourceBergen, empowers oncology physician practices and ensures their patients have access to the most innovative and cost-effective specialty care close to home. Through our ION Oncology Specialty GPO Network and Oncology Supply specialty distribution, along with our portfolio of integrated Specialty Solutions, we are a unified team of specialty practice partners, committed to building on our legacy of best-in-class service with meaningful innovation that supports our customers as they improve communities through patient-centric care. 

We are now Cencora and are uniting our 46,000+ team members under one identity in pursuit of a shared purpose: our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #21 on the Global Fortune 500 with more than $200 billion in annual revenue. Learn more at www.Cencora.com.

At Daiichi Sankyo, we create essential medicine for longer, better lives. Every day, we strive to put our skills at the service of those most in need. By uniting cutting-edge science and technology with a genuine interest in people, we develop high-quality, life-changing solutions for the patients of today and tomorrow with great care and unwavering dedication. We rely on reason, ingenuity, perseverance and empathy to make bold strides in oncology.

Our success comes from experts in collaboration: our people, scientists, health care providers, advocates – and patients themselves. Every partner on our journey, each passionately bringing their own skills and insights to bear, is essential. We seek out the patient voice and incorporate it into what we do each day, so that our continuous investment in cancer treatment research can make the biggest possible difference.

Building on a 125+-year heritage and a culture of innovation, we’re forging better futures through medicine for people everywhere. Together, we are creating new standards of care— our contribution to the enrichment of quality of life around the world. Please visit http://www.DaiichiSankyo.us .

Eisai Inc. is a human health care (hhc) company dedicated to pursuing innovative research and simplifying the treatment journey to help improve the lives of people affected by cancer, Alzheimer’s disease and other neurodegenerative conditions. Everything we do is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them.

Our hhc mission is the shared purpose that connects us to those we serve. It creates a network of powerful relationships that enable us to identify, understand and address unmet needs and healthcare disparities as we work towards achieving societal good.

Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. Our U.S. operations include discovery, research and development; manufacturing; global supply and logistics; and commercial activities.

To learn more, please visit https://us.eisai.com and connect with us on X and LinkedIn. For more information on our research, follow our dedicated neurology (LinkedIn  and X) and oncology (LinkedIn and X) pages.

Flatiron HealthⓇ is a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology. We’re partnering with cancer centers to deliver a better patient experience, strengthen practice financial health, and close the gap between care and research.

Founded more than 40 years ago as the first biotechnology company, Genentech is dedicated to the rigorous pursuit of science and the development and delivery of life-changing medicines for people facing serious diseases. Headquartered in South San Francisco, California and a proud member of the Roche Group, our community is united by a common purpose and sense of urgency to transform the future of healthcare. Learn more at gene.com.

Geron is a biopharmaceutical company that is charting a new course with the goal to deliver innovative treatment options for people living with blood cancer. Our tireless pursuit to improve outcomes for these patients resulted in the U.S. approval of the first ever telomerase inhibitor for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. As the sole company with an oligonucleotide telomerase inhibitor approved by the FDA, we feel a deep urgency to bring the potential power of telomerase inhibition to patients in need. We are conducting research in other blood cancers with high unmet need beyond LR-MDS, with ongoing clinical trials across other hematologic malignancies, including a pivotal Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF). We are proud of the impact this Nobel-winning science is having in the fight against blood cancers. At Geron, we are united by a shared purpose: Every individual in every role can meaningfully contribute to our mission to change lives by changing the course of blood cancer. With a culture rooted in courage and determination, we will continue to innovate and pursue new possibilities for patients.

GSK is a focused, global biopharma company. Our purpose is to unite science, technology and talent to get ahead of disease together and positivity impact the health of billions of people.

Ipsen is a global biopharmaceutical company focused on innovation and specialty care, At Ipsen, we develop and commercialize medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Disease. Our focus in oncology is on some of the most difficult-to-treat cancers. We have a growing portfolio of therapies for solid tumors and in hematology aimed at improving the lives of people living with pancreatic cancer, follicular lymphoma, epithelioid sarcoma, gastrointestinal and pancreatic neuroendocrine tumors, and carcinoid syndrome. Every day, our more than 5,000 employees worldwide, including nearly 800 in North America, work diligently to improve lives around the world. For more information, please visit www.ipsen.com/us

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. We are a leader in sleep disorders and epilepsy; further developing in movement disorders and PTSD; and focused on hematologic malignancies and solid tumors. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules, biologics, innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.

ABOUT JOHNSON & JOHNSON
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.janssen.com/johnson-johnson-innovative-medicine . Follow us at @JanssenUS and @JNJInnovMed . Janssen Research & Development, LLC, Janssen Scientific Affairs, LLC. and Janssen Biotech, Inc. are all Johnson & Johnson companies.

At Kite, our singular focus is cell therapy to treat and cure cancer. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit. 

We believe cell therapy has the ability to change the way cancer is treated. Our cell therapy technology uses the power of a patient's own immune system (their white blood cells) to target and attack their cancer cells. 

Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn.

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer.  The potential to bring new hope to people with cancer drives our purpose and our commitment.  As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types. 

Navista is a clinician-designed oncology practice alliance that offers advanced services, technology and financial support to help community practices remain independent and fuel their growth. Our mission is to empower community practices to deliver personalized, patient-centered cancer care, close to home. Navista includes more than 130 providers delivering multidisciplinary oncology and urology care at more than 50 practice sites across 10 states. As a Cardinal Health company, we have the resources to invest in our alliance member practices for long-term growth. Together with our members, Navista unlocks the power of community oncology to help practices stay independent—for the good of their patients, practice and community. To learn more, visit Navista.com or follow us on LinkedIn. 

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives.

We are a family-owned company innovating in iron metabolism, blood disorders, and cell cycle biology. With 700+ employees globally, we prioritize quality, collaboration, and patient care to drive life-changing treatments.

Stemline Therapeutics, a part of the Menarini Group, is focused on the development and commercialization of novel oncology therapeutics.

The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics.

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment.

At Takeda Oncology, we aspire to cure cancer, with inspiration from our patients and innovation from everywhere.  We ensure a tight connection from research to development to commercialization and rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to patients.  Our demonstrated leadership in the treatment of hematologic cancers and solid tumors combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches enable us to bring novel medicines to patients worldwide.

The US Oncology Network and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers.

Zydus Pharmaceuticals (USA) Inc. is a division of Zydus Lifesciences Limited - a global healthcare provider for over 70 years. 

Our mission is to unlock new possibilities in life sciences by delivering high-quality healthcare solutions that impact lives.  We have grown into one of the leading generic pharmaceutical companies in the U.S., driven by our commitment to excellent service for both customers and patients who rely on our products.

Zydus Pharmaceuticals continues to expand its portfolio in the U.S. market, introducing novel and innovative treatment options.